NCT00297024

Brief Summary

Brain tumours often have low oxygen levels, and that makes them more resistant to radiation therapy. If patients breathe the right mixture of oxygen during treatment, radiation may work better. In this study, patients with brain tumour will undergo a special MRI test while they breathe different mixtures of oxygen and carbon dioxide to find out whether oxygen levels improve in the tumor. Patients will also be asked to repeat this MRI test during the second week of radiation therapy, as well as 3 months, 6 months and 1 year after RT. The MRI test after RT will help us understand how the blood vessels in the normal brain are affected by radiation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Feb 2005

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2005

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

February 23, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 27, 2006

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

January 6, 2014

Status Verified

January 1, 2014

Enrollment Period

8.2 years

First QC Date

February 23, 2006

Last Update Submit

January 3, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • - To measure the inter-patient variability of change in tumour oxygenation with carbogen adminstration using MRI

    2 years

Secondary Outcomes (4)

  • - To determine whether modulation of oxygen and carbon dioxide administration can improve tumour oxygenation relative to standard carbogen breathing on MRI

    2 years

  • - To determine whether changes in tumour oxygenation with carbogen administration are different during the second week of radiotherapy compared to baseline measurements

    2 years

  • - To determine whether the normal brain cerebrovascular reactivity (CVR) measured with MRI changes through a course of radiotherapy and follow-up

    2 years

  • - To determine whether CVR differs between radiation exposed and non-exposed normal brain tissue in a given patient after radiotherapy

    2 years

Study Arms (1)

MRI for brain mets

EXPERIMENTAL
Procedure: MRI

Interventions

MRIPROCEDURE

Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.

MRI for brain mets

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with primary gliomas visible on MRI who are planning to receive radiotherapy or
  • Patients with brain metastases\>1cm who are planning to receive radiotherapy
  • Karnofsky Performance Status \>60
  • Age 18 years
  • Patients must be willing to visit Toronto Western Hospital for at least one MRI scan prior radiotherapy

You may not qualify if:

  • Seizures not controlled with medications, or non compliance with prescribed anti-seizure medication
  • Prior radiation therapy to the brain
  • Pregnancy
  • Unwilling or unable to co-operate with breathing maneuvers
  • Respiratory or cardiac limitations to breathing at 20 L/min
  • Medical contra-indications to limited hypercapnia or hypocapnia (known increased intracerebral pressure, metabolic acidosis or alkalosis)
  • Contraindication to MRI (patients weighing\>136 kgs-weight limit for the scanner tables; allergy to MR contrast agent; patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI)
  • Other medical conditions deemed by the PI or associates to make the patients ineligible for protocol procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Health Network

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Cynthia Ménard, MD

    Princess Margaret Hospital, Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 23, 2006

First Posted

February 27, 2006

Study Start

February 1, 2005

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

January 6, 2014

Record last verified: 2014-01

Locations